Absorption of fumonisin B1 and aminopentol on an in vitro model of intestinal epithelium; the role of P-glycoprotein

Toxicon. 2005 Mar 1;45(3):285-91. doi: 10.1016/j.toxicon.2004.10.015. Epub 2004 Dec 10.

Abstract

The aim of the present paper is to evaluate the absorption of fumonisin B1 and its principal metabolite, aminopentol on a human intestinal model, Caco-2 cells, cultured on semi-permeable inserts, that reproduces the two different intestinal compartments: luminal (apical) and serosal (basolateral) side. Following separate exposure in apical and in basolateral compartments, aminopentol passage through the cell layer (in particular from basolateral to apical direction) was shown, while it was not observed for the parent compound. The different aminopentol distribution between the two compartments of the culture system, and its variation in presence of verapamil or probenecid (P-gp and MRP inhibitors respectively), strongly suggests the involvement of P-glycoprotein in the influx/efflux mechanisms of aminopentol in the intestinal cells, reducing its oral bioavailability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / physiology*
  • Caco-2 Cells
  • Carboxylic Acids / pharmacokinetics*
  • Carboxylic Acids / pharmacology
  • Fumonisins / pharmacokinetics*
  • Fumonisins / pharmacology
  • Humans
  • Intestinal Absorption / physiology*
  • Membrane Potentials / drug effects
  • Models, Biological
  • Mycotoxins / pharmacokinetics*
  • Mycotoxins / pharmacology
  • Probenecid / pharmacology
  • Verapamil / pharmacology

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Carboxylic Acids
  • Fumonisins
  • Mycotoxins
  • aminopentol
  • fumonisin B1
  • Verapamil
  • Probenecid